Experts preview top HR+ and HER2+ breast cancer abstracts ahead of ASCO 2026
Preparations are under way for the 2026 ASCO Annual Meeting, and breast cancer updates are generating strong interest among clinicians.
Leading oncologists including Dr. Yara Abdou of UNC, Dr. VK Gadi of the University of Illinois, Dr. Erika Hamilton of Sarah Cannon Research Institute, and Dr. Kevin Kalinsky of Emory University highlighted the abstracts they are most eager to see, focusing on hormone-receptor-positive (HR+) and HER2-positive disease.
The preview outlines the key presentations expected to shape future research and treatment strategies, offering attendees a roadmap of the most promising data to watch at the conference.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go”
read at onclive ↗
comments(0)
5-min edit window · permanent after that